GlycoMimetics Revenue, Profits - GLYC Quarterly Income Statement

Add to My Stocks
$14.58 $0.67 (4.82%) GLYC stock closing price Sep 18, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking GlycoMimetics stock price alone is not sufficient. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from - to - and how operating and non operating activities have impacted the GLYC stock. The operating expenses as shown in the GlycoMimetics profit and loss statement for 2018 Q2 total to $12.15M. This line item shows that the operating expenses has increased compared with last year. Also check: GlycoMimetics assets and GlycoMimetics free cash flow.

View and download details of revenue and profits for GlycoMimetics for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
GlycoMimetics Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
GlycoMimetics Gross Profit
----------
Research & Development Expense9.3M9.02M6.74M5.77M5.72M5.87M6.07M5.92M5.78M5.51M
Selling General & Admin Expense2.85M2.85M2.82M2.4M2.52M2.09M2.31M1.98M2.31M2.05M
Income Before Depreciation Depletion Amortization-12.15M-11.87M-9.54M-8.18M-8.24M-7.97M-8.37M-7.88M-8.09M-7.57M
Depreciation Depletion Amortization----------
Non Operating Income----------
Interest Expense----------
GlycoMimetics Pretax Income
-11.28M-11.51M-9.26M-7.95M-8.14M-7.93M-8.33M-7.85M-8.07M-7.55M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-11.28M-11.51M-9.26M-7.95M-8.14M-7.93M-8.33M-7.86M-8.07M-7.56M
Extraordinary Items & Discontinued Operations----------
GlycoMimetics Profit/ Loss (Net Income)
-11.28M-11.51M-9.26M-7.95M-8.14M-7.93M-8.33M-7.86M-8.07M-7.56M
Average Shares used to compute Diluted EPS42.81M35.16M34.14M32.72M27.24M23.48M23.11M23.05M19.79M19.07M
Average Shares used to compute Basic EPS42.81M35.16M34.14M32.72M27.24M23.48M23.11M23.05M19.79M19.07M
Income Before Nonrecurring Items-11.28M-11.51M-9.26M-7.95M-8.14M-7.93M-8.33M-7.86M-8.07M-7.56M
Income from Nonrecurring Items----------
GlycoMimetics Earnings Per Share Basic Net
-0.26-0.33-0.27-0.24-0.30-0.34-0.36-0.34-0.41-0.40
GlycoMimetics Earnings Per Share Diluted Net
-0.26-0.33-0.27-0.24-0.30-0.34-0.36-0.34-0.41-0.40
EPS Diluted Before Nonrecurring Items-0.26-0.33-0.27-0.24-0.30-0.34-0.36-0.34-0.41-0.40
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

GlycoMimetics stock analysis involves checking at least a few of the important things like:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: GlycoMimetics revenue chart, implies that the company is growing. It has not been the case with GlycoMimetics. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: Most businesses like GlycoMimetics try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The GLYC financials along with GlycoMimetics historical stock prices provide a lot of details about the firm.

GlycoMimetics Income Statement - Key Financial Ratios

Operating Margin
0
Net Profit Margin
0

Other Income Statements - GlycoMimetics Inc Industry Peers

bluebird bio income statement, Emisphere Tech income statement, SANGAMO THERAP income statement